share_log

Condom Maker Karex Gets 'Outperform' Tag Kenanga Research Initiation Report

Condom Maker Karex Gets 'Outperform' Tag Kenanga Research Initiation Report

避孕套製造商Karex獲得 “跑贏大盤” 標籤 Kenanga研究啓動報告
The Malaysian Reserve ·  02/05 20:20

Karex Bhd, the world's largest condom manufacturer, is riding on the strong growth, focusing on high-margin products which will take its profitability to a higher level, according to a local research house.

當地一家研究機構稱,全球最大的避孕套製造商Karex Bhd正在利用強勁的增長,專注於高利潤率的產品,這將使其盈利能力更上一層樓。

"It is penetrating high-growth markets with premium offerings backed by innovation and strict compliance with international standards. We project its earnings to double in FY24, followed by another 88% surge in FY25," according to Kenanga Research.

“它以創新和嚴格遵守國際標準爲後盾的優質產品正在打入高增長市場。根據Kenanga Research的數據,我們預計其收益將在24財年翻一番,隨後在25財年再增長88%。

In an initiation report released today, it has badged the counter as 'Outperform' with a 52- week target price of RM1.00. The stock was trading unchanged at 78 sen at 10am today.

在今天發佈的啓動報告中,該公司將該股評爲 “跑贏大盤”,52周目標價爲1.00令吉。今天上午10點,該股的交易價格維持在78仙不變。

The report noted that the global condom market was on an impressive growth trajectory, projected to nearly double from US$8-9 billion in 2022 to US$19-23 billion by 2032, with a robust compound annual growth rate (CAGR) of 8%-9%.

該報告指出,全球避孕套市場正處於令人印象深刻的增長軌道上,預計將從2022年的80-90億美元增加到2032年的190億至230億美元,強勁的複合年增長率(CAGR)爲8%-9%。

The surge was fuelled by heightened consumer awareness, a diverse array of products catering to varied preferences, and global initiatives to curb sexually transmitted diseases (STDs) and sexually transmitted infections (STIs), it said.

它說,這種激增是由消費者意識的提高、滿足不同偏好的各種產品以及遏制性傳播疾病(STD)和性傳播感染(STI)的全球舉措推動的。

"Karex, being the world largest condom manufacturer with a 20% market share and producing up to 5.5 billion pieces annually, is well-equipped to ride rising industry demand," it said.

它說:“Karex是全球最大的避孕套製造商,擁有20%的市場份額,年產量高達55億片,完全有能力應對不斷增長的行業需求。”

Amid a decade marked by stiff competition and the impact of the pandemic, it said Karex has successfully shifted its focus to high-margin products and segments, especially in its commercial and original brand manufacturing (OBM) segments.

該公司表示,在競爭激烈和疫情影響的十年中,Karex成功地將重點轉移到高利潤的產品和細分市場上,尤其是在商業和原創品牌製造(OBM)領域。

It said the strategic redirection has substantially boosted the company's profitability, with these segments yielding gross profit margins significantly higher than the tender market, at 20%-25% and over 50% compared to 7%-10%.

該公司表示,戰略重定向極大地提高了公司的盈利能力,這些細分市場的毛利率明顯高於招標市場,爲20%-25%,超過50%,而7%-10%。

In 1QFY24, despite a slight reduction in revenue, it said Karex achieved 'impressive increases in both gross profit and operating profit margins', underlining the company's resilience and the effectiveness of its strategy in targeting more profitable segments.

在 1QFY24 中,儘管收入略有下降,但該公司表示,Karex實現了 “毛利潤率和營業利潤率的驚人增長”,這突顯了該公司的彈性及其戰略在瞄準利潤更高的細分市場方面的有效性。

"We expect Karex to achieve a significant 24% annual revenue growth in FY24 and FY25, spurred by increased activity in its commercial, OBM, and tender segments. The company's profit margins are likely to see an uplift due to an advantageous product and segment mix, along with stable costs for raw materials and freight.

“我們預計,受商業、OBM和招標領域活動增加的推動,Karex將在24財年和25財年實現24%的顯著年收入增長。由於優勢的產品和細分市場組合以及穩定的原材料和運費成本,該公司的利潤率可能會提高。

"This is expected to lead to a substantial net profit increase, with a projection of a 113% rise to RM22 million in FY24, and a further 88% growth to RM42 million in FY25," it said.

它說:“預計這將導致淨利潤大幅增長,預計24財年將增長113%至2,200萬令吉,並在25財年進一步增長88%至4200萬令吉。”

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論